Les données avaient été présentées récemment au CCR26. La prépublication est enfin disponible dans le Lancet.
Le TAMIFLU est inutile, voire délétère chez les patients de réanimation avec grippe grave. Je le dis depuis pfiooouuu, 10 ans, mais on ne m'écoute jamais ;)
papers.ssrn.com/sol3/papers....
Le TAMIFLU est inutile, voire délétère chez les patients de réanimation avec grippe grave. Je le dis depuis pfiooouuu, 10 ans, mais on ne m'écoute jamais ;)
papers.ssrn.com/sol3/papers....
Oseltamivir for Critically Ill Patients with Influenza: A Randomised Trial
Background: The antiviral oseltamivir is widely used for the treatment of critically ill patients with influenza. Evidence from randomised trials about its eff
papers.ssrn.com
August 12, 2026 at 1:47 PM
Les données avaient été présentées récemment au CCR26. La prépublication est enfin disponible dans le Lancet.
Le TAMIFLU est inutile, voire délétère chez les patients de réanimation avec grippe grave. Je le dis depuis pfiooouuu, 10 ans, mais on ne m'écoute jamais ;)
papers.ssrn.com/sol3/papers....
Le TAMIFLU est inutile, voire délétère chez les patients de réanimation avec grippe grave. Je le dis depuis pfiooouuu, 10 ans, mais on ne m'écoute jamais ;)
papers.ssrn.com/sol3/papers....
Once again, for those at the back, the effort to refute bulls*t is 10x that required to produce it. Can we please stop doing high dose Vit C trials in critical care now?
High-Dose Vitamin C in Burns
Time to Stop
🆕🔥🟢VICTORY RCT
High-dose intravenous vitamin C did not reduce mortality and organ dysfunction and may be associated with harm in patients with severe burn injury #EMIMCC
jamanetwork.com/journals/jam...
Time to Stop
🆕🔥🟢VICTORY RCT
High-dose intravenous vitamin C did not reduce mortality and organ dysfunction and may be associated with harm in patients with severe burn injury #EMIMCC
jamanetwork.com/journals/jam...
June 12, 2026 at 7:35 PM
Maps & Publications
Annual Drinking Water Quality Report (Consumer Confidence Report) is available at apexnc.org/CCR26 (replacing the previous DocumentCenter PDF link).
apexnc.org/606
Annual Drinking Water Quality Report (Consumer Confidence Report) is available at apexnc.org/CCR26 (replacing the previous DocumentCenter PDF link).
apexnc.org/606
www.apexnc.org
May 15, 2026 at 1:09 PM
Maps & Publications
Annual Drinking Water Quality Report (Consumer Confidence Report) is available at apexnc.org/CCR26 (replacing the previous DocumentCenter PDF link).
apexnc.org/606
Annual Drinking Water Quality Report (Consumer Confidence Report) is available at apexnc.org/CCR26 (replacing the previous DocumentCenter PDF link).
apexnc.org/606
It was wonderful to have you join us @ccctg.bsky.social at #CCR26!
4 superb Canadian, or Canadian led, trials no less!
#FISSH #SAVE-ICU #VICTORY & #Oseltamivir (with REMAP-CAP)
Looking forward to more great trials from the original critical care trials group
4 superb Canadian, or Canadian led, trials no less!
#FISSH #SAVE-ICU #VICTORY & #Oseltamivir (with REMAP-CAP)
Looking forward to more great trials from the original critical care trials group
One photo, countless collaborations 🌍
The CCCTG 🍁 contingent at @criticalcarereviews.com in Belfast last week, connecting with colleagues from around the world to advance critical care and improve outcomes for our sickest patients #CCR26
The CCCTG 🍁 contingent at @criticalcarereviews.com in Belfast last week, connecting with colleagues from around the world to advance critical care and improve outcomes for our sickest patients #CCR26
June 16, 2026 at 10:28 PM
It was wonderful to have you join us @ccctg.bsky.social at #CCR26!
4 superb Canadian, or Canadian led, trials no less!
#FISSH #SAVE-ICU #VICTORY & #Oseltamivir (with REMAP-CAP)
Looking forward to more great trials from the original critical care trials group
4 superb Canadian, or Canadian led, trials no less!
#FISSH #SAVE-ICU #VICTORY & #Oseltamivir (with REMAP-CAP)
Looking forward to more great trials from the original critical care trials group
Missed any of CCR26?
Want to watch it again?
The unedited recording of the entire conference is now freely available for a few days before being taken down & edited.
Enjoy the best critical care trials in the world!
https://criticalcarereviews.com/
Want to watch it again?
The unedited recording of the entire conference is now freely available for a few days before being taken down & edited.
Enjoy the best critical care trials in the world!
https://criticalcarereviews.com/
June 14, 2026 at 10:53 AM
Missed any of CCR26?
Want to watch it again?
The unedited recording of the entire conference is now freely available for a few days before being taken down & edited.
Enjoy the best critical care trials in the world!
https://criticalcarereviews.com/
Want to watch it again?
The unedited recording of the entire conference is now freely available for a few days before being taken down & edited.
Enjoy the best critical care trials in the world!
https://criticalcarereviews.com/
#CCR26 ABC post-ICU - RESULTS
Liberal vs. restrictive transfusion strategy post-ICU: more blood used in liberal group (~2 units)
Primary outcome: No difference in SF-36 PCS at 90 days
No difference in sensitivity analyses
Does this re-assure re. allowing low Hb post-ICU?
Liberal vs. restrictive transfusion strategy post-ICU: more blood used in liberal group (~2 units)
Primary outcome: No difference in SF-36 PCS at 90 days
No difference in sensitivity analyses
Does this re-assure re. allowing low Hb post-ICU?
June 12, 2026 at 2:49 PM
#CCR26 ABC post-ICU - RESULTS
Liberal vs. restrictive transfusion strategy post-ICU: more blood used in liberal group (~2 units)
Primary outcome: No difference in SF-36 PCS at 90 days
No difference in sensitivity analyses
Does this re-assure re. allowing low Hb post-ICU?
Liberal vs. restrictive transfusion strategy post-ICU: more blood used in liberal group (~2 units)
Primary outcome: No difference in SF-36 PCS at 90 days
No difference in sensitivity analyses
Does this re-assure re. allowing low Hb post-ICU?
#CCR26 Last trial of the day, ABC post-ICU evaluating liberal RBC transfusion (aiming Hb 100-120) vs. restrictive (Hb 70-90).
Send us your questions online or on the chat function within the free livestream at criticalcarereviews.com
Send us your questions online or on the chat function within the free livestream at criticalcarereviews.com
Home
The most up-to-date critical care website in the world
criticalcarereviews.com
June 12, 2026 at 2:36 PM
#CCR26 Last trial of the day, ABC post-ICU evaluating liberal RBC transfusion (aiming Hb 100-120) vs. restrictive (Hb 70-90).
Send us your questions online or on the chat function within the free livestream at criticalcarereviews.com
Send us your questions online or on the chat function within the free livestream at criticalcarereviews.com
#CCR26 Dr Murthy also co-wrote an editorial for the GASTRIC-PICU study in @JAMA.com
👇
https://t.co/Z79Deerk6V
👇
https://t.co/Z79Deerk6V
https://t.co/Z79Deerk6V
Invalid response status code (403)
t.co
June 12, 2026 at 10:36 AM
#CCR26 Dr Murthy also co-wrote an editorial for the GASTRIC-PICU study in @JAMA.com
👇
https://t.co/Z79Deerk6V
👇
https://t.co/Z79Deerk6V
#CCR26 GASTRIC-PICU study editorial is provided by Dr Srinivas Murthy (Vancouver), and begins by also commenting on the brilliant trial logo for the study, and surveying the in-person audience about their routine practice re. GRV!
What do you do (adults and paediatrics) re. GRV?
What do you do (adults and paediatrics) re. GRV?
June 12, 2026 at 10:34 AM
#CCR26 GASTRIC-PICU study editorial is provided by Dr Srinivas Murthy (Vancouver), and begins by also commenting on the brilliant trial logo for the study, and surveying the in-person audience about their routine practice re. GRV!
What do you do (adults and paediatrics) re. GRV?
What do you do (adults and paediatrics) re. GRV?
#CCR26 GASTRIC-PICU results were presented by Prof Lyvonne Tume and ProfDavid Harrison
Results are now available in @JAMA_current and the panel discussion will include Dr Chris Seymour (Assoc. editor for critical care at JAMA)
https://t.co/TgbqH5u1Kt
Do these results change your practice?
Results are now available in @JAMA_current and the panel discussion will include Dr Chris Seymour (Assoc. editor for critical care at JAMA)
https://t.co/TgbqH5u1Kt
Do these results change your practice?
https://t.co/TgbqH5u1Kt
Invalid response status code (403)
t.co
June 12, 2026 at 10:30 AM
#CCR26 GASTRIC-PICU results were presented by Prof Lyvonne Tume and ProfDavid Harrison
Results are now available in @JAMA_current and the panel discussion will include Dr Chris Seymour (Assoc. editor for critical care at JAMA)
https://t.co/TgbqH5u1Kt
Do these results change your practice?
Results are now available in @JAMA_current and the panel discussion will include Dr Chris Seymour (Assoc. editor for critical care at JAMA)
https://t.co/TgbqH5u1Kt
Do these results change your practice?
#CCR26 GASTRIC-PICU:
Survival and days free of IMV at 30d: 25 (21-27) days in both groups (adjusted OR, 0.95 [95% CI, 0.86-1.05]; within non-inferiority margin.
Mean % est. energy requirements by 72 hours: 80.3% intervention vs. 76.8% usual care; P < .001
Practice changing?
Survival and days free of IMV at 30d: 25 (21-27) days in both groups (adjusted OR, 0.95 [95% CI, 0.86-1.05]; within non-inferiority margin.
Mean % est. energy requirements by 72 hours: 80.3% intervention vs. 76.8% usual care; P < .001
Practice changing?
June 12, 2026 at 10:22 AM
#CCR26 GASTRIC-PICU:
Survival and days free of IMV at 30d: 25 (21-27) days in both groups (adjusted OR, 0.95 [95% CI, 0.86-1.05]; within non-inferiority margin.
Mean % est. energy requirements by 72 hours: 80.3% intervention vs. 76.8% usual care; P < .001
Practice changing?
Survival and days free of IMV at 30d: 25 (21-27) days in both groups (adjusted OR, 0.95 [95% CI, 0.86-1.05]; within non-inferiority margin.
Mean % est. energy requirements by 72 hours: 80.3% intervention vs. 76.8% usual care; P < .001
Practice changing?
#CCR26 GASTRIC-PICU:
P: Children ≤16y fed via gastric route + receiving IMV
I: No routine GRV measurement
C: Usual care (inc. GRV assessments ≤6h)
O: Co-primary: Composite of survival MV-free days (noninferiority) + % estimated energy requirements achieved by 72h (superiority)
P: Children ≤16y fed via gastric route + receiving IMV
I: No routine GRV measurement
C: Usual care (inc. GRV assessments ≤6h)
O: Co-primary: Composite of survival MV-free days (noninferiority) + % estimated energy requirements achieved by 72h (superiority)
June 12, 2026 at 10:17 AM
#CCR26 GASTRIC-PICU:
P: Children ≤16y fed via gastric route + receiving IMV
I: No routine GRV measurement
C: Usual care (inc. GRV assessments ≤6h)
O: Co-primary: Composite of survival MV-free days (noninferiority) + % estimated energy requirements achieved by 72h (superiority)
P: Children ≤16y fed via gastric route + receiving IMV
I: No routine GRV measurement
C: Usual care (inc. GRV assessments ≤6h)
O: Co-primary: Composite of survival MV-free days (noninferiority) + % estimated energy requirements achieved by 72h (superiority)
#CCR26 Gastric-PICU aimed to determine the clinical and cost-effectiveness of not routinely measuring gastric residual volume (GRV) to guide enteral feeding and to determine if it is inferior to standard, at least 6h, GRV assessment in mechanically ventilated children in PICU
June 12, 2026 at 10:09 AM
#CCR26 Gastric-PICU aimed to determine the clinical and cost-effectiveness of not routinely measuring gastric residual volume (GRV) to guide enteral feeding and to determine if it is inferior to standard, at least 6h, GRV assessment in mechanically ventilated children in PICU
#CCR26 Now that we're caffeinated, it's time for the GASTRIC-PICU study, with most definitely the best study mascot of this week! George the gastric giraffe!
June 12, 2026 at 10:03 AM
#CCR26 Now that we're caffeinated, it's time for the GASTRIC-PICU study, with most definitely the best study mascot of this week! George the gastric giraffe!
#CCR26 Now we have an editorial from nephrologist/intensivist Prof Marlies Ostermann
Send us your questions or reactions here, or in the chat function of the free, online stream of CCR26 at criticalcarereviews.com
Send us your questions or reactions here, or in the chat function of the free, online stream of CCR26 at criticalcarereviews.com
Home
The most up-to-date critical care website in the world
criticalcarereviews.com
June 12, 2026 at 8:34 AM
#CCR26 Now we have an editorial from nephrologist/intensivist Prof Marlies Ostermann
Send us your questions or reactions here, or in the chat function of the free, online stream of CCR26 at criticalcarereviews.com
Send us your questions or reactions here, or in the chat function of the free, online stream of CCR26 at criticalcarereviews.com
#CCR26 SODa-BIC results!
Major adverse kidney event within 30 days:
98 / 244 patients (40.2%) in sodium bicarbonate group;
100 of 254 patients (39.4%) in the placebo group
(adj. diff. 1.2% points; 95% CI, −7.1 to 9.4; P=0.78)
Now in @nejm.org 👇
https://www.nejm.org/doi/full/10.1056/NEJMoa2600526
Major adverse kidney event within 30 days:
98 / 244 patients (40.2%) in sodium bicarbonate group;
100 of 254 patients (39.4%) in the placebo group
(adj. diff. 1.2% points; 95% CI, −7.1 to 9.4; P=0.78)
Now in @nejm.org 👇
https://www.nejm.org/doi/full/10.1056/NEJMoa2600526
https://www.nejm.org/doi/full/10.1056/NEJMoa2600526
Invalid response status code (403)
www.nejm.org
June 12, 2026 at 8:29 AM
#CCR26 SODa-BIC results!
Major adverse kidney event within 30 days:
98 / 244 patients (40.2%) in sodium bicarbonate group;
100 of 254 patients (39.4%) in the placebo group
(adj. diff. 1.2% points; 95% CI, −7.1 to 9.4; P=0.78)
Now in @nejm.org 👇
https://www.nejm.org/doi/full/10.1056/NEJMoa2600526
Major adverse kidney event within 30 days:
98 / 244 patients (40.2%) in sodium bicarbonate group;
100 of 254 patients (39.4%) in the placebo group
(adj. diff. 1.2% points; 95% CI, −7.1 to 9.4; P=0.78)
Now in @nejm.org 👇
https://www.nejm.org/doi/full/10.1056/NEJMoa2600526
#CCR26 SODA-BIC overview:
P: Patients receiving vasopressors, + dedicated IV line + metabolic acidosis
I: 8.4% Sodium bicarb (titrated to pH)
C: 5% dextrose
O: Major adverse kidney events within 30 days
Protocol + SAP 👉 https://www.sciencedirect.com/science/article/pii/S1441277225000122
P: Patients receiving vasopressors, + dedicated IV line + metabolic acidosis
I: 8.4% Sodium bicarb (titrated to pH)
C: 5% dextrose
O: Major adverse kidney events within 30 days
Protocol + SAP 👉 https://www.sciencedirect.com/science/article/pii/S1441277225000122
https://www.sciencedirect.com/science/article/pii/S1441277225000122
Forbidden by robots.txt
www.sciencedirect.com
June 12, 2026 at 8:23 AM
#CCR26 SODA-BIC overview:
P: Patients receiving vasopressors, + dedicated IV line + metabolic acidosis
I: 8.4% Sodium bicarb (titrated to pH)
C: 5% dextrose
O: Major adverse kidney events within 30 days
Protocol + SAP 👉 https://www.sciencedirect.com/science/article/pii/S1441277225000122
P: Patients receiving vasopressors, + dedicated IV line + metabolic acidosis
I: 8.4% Sodium bicarb (titrated to pH)
C: 5% dextrose
O: Major adverse kidney events within 30 days
Protocol + SAP 👉 https://www.sciencedirect.com/science/article/pii/S1441277225000122
#CCR26 Dr Serpa Neto reminds us of the physiology underpinning sodium bicarbonate, before talking through some past studies of sodium bicarbonate in metabolic acidosis. Interesting to see the variation in practice with sodium bicarbonate!
Do you use bicarb for metabolic acidosis?
Do you use bicarb for metabolic acidosis?
June 12, 2026 at 8:09 AM
#CCR26 Dr Serpa Neto reminds us of the physiology underpinning sodium bicarbonate, before talking through some past studies of sodium bicarbonate in metabolic acidosis. Interesting to see the variation in practice with sodium bicarbonate!
Do you use bicarb for metabolic acidosis?
Do you use bicarb for metabolic acidosis?
#CCR26 Friday, SODa-BIC to get us started. Our second bicarb study of the week! Chaired by Prof Charuhas Thakar (Queen's University Belfast) and the trial is presented this morning by Dr Ary Serpa Neto
June 12, 2026 at 8:04 AM
#CCR26 Friday, SODa-BIC to get us started. Our second bicarb study of the week! Chaired by Prof Charuhas Thakar (Queen's University Belfast) and the trial is presented this morning by Dr Ary Serpa Neto
#CCR26 Last up for today is a review of the top critical care clinical trials published in the past 12 months, and presented by Dr Ellen Gorman
Tune in live, and for free, to hear a rapid overview of recent top trials at criticalcarereviews.com
Tune in live, and for free, to hear a rapid overview of recent top trials at criticalcarereviews.com
http://criticalcarereviews.co
Invalid response status code (0)
criticalcarereviews.co
June 11, 2026 at 3:36 PM
#CCR26 Last up for today is a review of the top critical care clinical trials published in the past 12 months, and presented by Dr Ellen Gorman
Tune in live, and for free, to hear a rapid overview of recent top trials at criticalcarereviews.com
Tune in live, and for free, to hear a rapid overview of recent top trials at criticalcarereviews.com
#CCR26 Delve into the ACCOMPLISH trial - published today in JAMA Network Open
👇
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2850152
👇
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2850152
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2850152
Invalid response status code (403)
jamanetwork.com
June 11, 2026 at 3:29 PM
#CCR26 Delve into the ACCOMPLISH trial - published today in JAMA Network Open
👇
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2850152
👇
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2850152
#CCR26 Professor Jo McPeake (Cambridge) provides an editorial for the ACCOMPLISH trial. She highlights how a prediction model was used to support participant inclusion, and the risks that predictive models may bias against some patient populations.
June 11, 2026 at 3:00 PM
#CCR26 Professor Jo McPeake (Cambridge) provides an editorial for the ACCOMPLISH trial. She highlights how a prediction model was used to support participant inclusion, and the risks that predictive models may bias against some patient populations.
#CCR26 ACCOMPLISH trial - no difference in number of days spent at home within 90 days after hospital discharge between usual care and the four remote monitoring arms
But Dr Yende shows some data that suggests there may be heterogeneity of treatment effect based on patient age
But Dr Yende shows some data that suggests there may be heterogeneity of treatment effect based on patient age
June 11, 2026 at 2:51 PM
#CCR26 ACCOMPLISH trial - no difference in number of days spent at home within 90 days after hospital discharge between usual care and the four remote monitoring arms
But Dr Yende shows some data that suggests there may be heterogeneity of treatment effect based on patient age
But Dr Yende shows some data that suggests there may be heterogeneity of treatment effect based on patient age
#CCR26 ACCOMPLISH was an adaptive platform trial that aimed to compare effectiveness of different care models to prevent readmissions for patients hospitalized with sepsis or LRTI. The primary outcome was number of days spent at home within 90 days after hospital discharge.
June 11, 2026 at 2:40 PM
#CCR26 ACCOMPLISH was an adaptive platform trial that aimed to compare effectiveness of different care models to prevent readmissions for patients hospitalized with sepsis or LRTI. The primary outcome was number of days spent at home within 90 days after hospital discharge.